Clinical Rheumatology (CLIN RHEUMATOL )

Publisher: International League of Associations for Rheumatology, Springer Verlag


Clinical Rheumatology is an international journal devoted to publishing in the English language original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level. Studies carried out anywhere in the world will be considered the basic criterion for acceptance being the medical and scientific standard of the work described.

  • Impact factor
    Show impact factor history
    Impact factor
  • 5-year impact
  • Cited half-life
  • Immediacy index
  • Eigenfactor
  • Article influence
  • Website
    Clinical Rheumatology website
  • Other titles
    Clinical rheumatology (Online)
  • ISSN
  • OCLC
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Springer Verlag

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Authors own final version only can be archived
    • Publisher's version/PDF cannot be used
    • On author's website or institutional repository
    • On funders designated website/repository after 12 months at the funders request or as a result of legal obligation
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany link to published version (The original publication is available at
    • Articles in some journals can be made Open Access on payment of additional charge
  • Classification
    ​ green

Publications in this journal

  • [show abstract] [hide abstract]
    ABSTRACT: Alcohol consumption had been linked to the risk of gout theoretically, but the results from observational studies were conflicting. Hence, a meta-analysis was conducted to assess the effect of alcohol consumption on the risk of gout. A comprehensive search was performed to identify all eligible studies on the association of alcohol consumption with gout risk. Pooled relative risks (RRs) with 95 % confidence intervals (CIs) from fixed and random effects models were calculated. A total of 12 articles with 17 studies involving 42,924 cases met the inclusion criteria. The pooled RR for highest vs. non/occasional alcohol drinking in every study was 1.98 (95 % CI, 1.52–2.58). The RRs for light (≤1 drink/day), moderate (>1 to <3 drinks/day), and heavy drinking (≥3 drinks/day) vs. non/occasional alcohol drinking were 1.16 (95 % CI, 1.07–1.25), 1.58 (95 % CI, 1.50–1.66), and 2.64 (95 % CI, 2.26–3.09), respectively. The results suggested that alcohol consumption might be associated with increased risk of gout.
    Clinical Rheumatology 11/2013;
  • [show abstract] [hide abstract]
    ABSTRACT: The aim was to investigate circulating levels of interelukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α, chemokine (C-X-C motif) ligand (CXCL)10, CXCL11 and chemokine (C-C motif) ligand (CCL)2 in "mixed cryoglobulinemia and hepatitis C" (MC + HCV). Serum levels of CXCL11, IL-1β, TNF-α, IL-6, and CCL2 were evaluated in 52 MC + HCV vs 52 sex- and age-matched controls to correlate them to the clinical features of mixed cryoglobulinemia. CXCL11 was significantly higher in MC + HCV than in controls (264 ± 279 vs 70 ± 16 pg/mL, respectively; P = 0.0002; univariate analysis of variance (ANOVA)), in particular in 23 MC + HCV with active vasculitis vs those without (293 ± 221 vs 168 ± 57 pg/mL, respectively; P < 0.001; ANOVA). Significantly high IL-1β, IL-6, TNF-α, CXCL10, and CCL2 in MC + HCV vs healthy controls were confirmed. In a multiple linear regression model (CXCL11 or CCL2, vs age, alanine aminotransferase, IL-1β, IL-6, TNF-α, and CXCL10), CXCL11 was significantly associated with high CXCL10 (P < 0.001), while CCL2 with high IL-6 (P < 0.001). This study demonstrates in MC + HCV high serum levels of (a) T-helper 1 chemokines, CXCL11 and CXCL10 (related to each other) and (b) proinflammatory cytokines IL-6 and CCL2 (related to each other).
    Clinical Rheumatology 04/2013;
  • Clinical Rheumatology 03/2013;
  • Clinical Rheumatology 01/2013;
  • Clinical Rheumatology 11/2012; 31(11):1549-57.
  • [show abstract] [hide abstract]
    ABSTRACT: Abstract Previously peripheral neuropathy signs have been reported in inflammatory chronic diseases but the presence of neuropathic pain syndrome (NPS) in Behcet’s disease (BD) is unclear. The aim of this study was to investigate the association of BD with NPS and impaired quality of life and sleep quality. A total of 111 patients diagnosed as BD and 52 healthy controls were included. Pain severity was assessed by visual analogue scale (VAS) in rest and during activity. The NPS was diagnosed according to the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) index. The well-being and sleep disturbances of the groups were evaluated with Psychological General Well-Being (PGWB) Scale and Pittsburg Sleep Quality Index (PSQI). Although there were no one with NPS in healthy controls, the proportion of NPS in patients with BD was 19.8 % (p0 0.001). The VAS scores both in activity and at rest were higher in BD (p<0.001). There was statistically significant decrease in total PGWB score in BD patients compared to healthy controls (p<0.001). And significant increase in LANSS score was observed in patients with BD compared to healthy controls (p00.000). The total LANSS scores showed significant positive correlation with PSQI scores (r00.322) and negative correlation with total PGWB scores (r0-0.672) in patients with BD. We observed a positive correlation between LANSS and VAS (rest and activity) scores (r00.44, r00.42 respectively). The NPS seems to be associated with BD which should be taken into consideration in patients with neuropathic signs. The quality of life (QoL) and quality of sleep of the patients with BD were found to be impaired and this may be due to the presence of NPS. Keywords Behcet’s disease . Neuropathic pain syndrome .
    Clinical Rheumatology 09/2012;
  • Source
    Clinical Rheumatology 01/2011; 30(1):151-151.
  • Source
    Clinical Rheumatology 01/2011; 30(1):153-153.
  • Source
    Clinical Rheumatology 01/2011; 30(1):155-155.
  • [show abstract] [hide abstract]
    ABSTRACT: Abstract Andrographis paniculata (Burm. f.) Wall ex Nees (Acanthaceae) possesses anti-inflammatory effects, attributed to the main constituent andrographolide proposed as alternative in the treatment of autoimmune disease. A prospective, randomized, double blind, and placebo-controlled study in patients with rheumatoid arthritis (RA) was performed. Tablets (Paractin®) made of an extract of A. paniculata (30% total andrographolides) were administered three times a day for 14 weeks, after a 2-week washout period to 60 patients with active RA. The primary outcomes were pain intensity measured using a horizontal visual analog pain scale (VAPS). In addition, ACR, EULAR, and SF36 clinical parameters were recorded. The intensity of joint pain decreased in the active vs placebo group at the end of treatment, although these differences were not statistically significant. A significant diminishing for week in tender joint −0.13 95% confidence interval (CI; −0.22 to 0.06; p=0.001), number of swollen joints −0.15 95%CI (−0.29 to −0.02; p= 0.02), total grade of swollen joint −0.27 95%CI (−0.48 to −0.07; p=0.010), number of tender joints −0.25 95%CI (−0.48 to −0.02; p=0.033), total grade of swollen joints −0.27 95%CI (−0.48 to −0.07; p=0.01), total grade of tender joints −0.47 95%CI (−0.77 to −0.17; p=0.002) and HAQ −0.52 95%CI (−0.82 to −0.21; p<0.001) and SF36 0.02 95% CI (0.01 to 0.02; p<0.001) health questionnaires was observed within the group with the active drug. Moreover, it was associated to a reduction of rheumatoid factor, IgA, and C4. These findings suggest that A. paniculata could be a useful “natural complement” in the treatment of AR; however, a larger trial and a more extended period of treatment is necessary in order to corroborate these results. Keywords Andrographis . Rheumatoid arthritis
    Clinical Rheumatology 03/2009;
  • [show abstract] [hide abstract]
    ABSTRACT: The aim in this study was to evaluate the effect of cervical spondylosis on vertebral arterial flow. The flow changes on Doppler measurements in patients with vertigo were also assessed. Ninety-one patients with different grades of degeneration on disks and apophysis were evaluated. The severity of degeneration was determined by two observers, and the effect of cervical degeneration on vertebral arterial flow was assessed. The relation between vertigo and changes in Doppler measurements of vertebral artery in neck and cranium was analyzed. As total degeneration increases, the flow volume decreases in the right vertebral artery but increases in the left. No other correlation between degeneration scores, cervical curve measurements, and Doppler measurements was noted. According to the total degeneration scores, no differences were noted between the patients with and without vertigo. In patients with vertigo, the resistive index was higher in the neck before the vertebral foramina. In correlations of the ratios of the intra/extracranial vertebral artery with Doppler measurements, the only change was observed in the left flow volume. The severity of degeneration in disks and apophysis does not cause a considerable change in vertebral arterial flow, and also no significant finding on Doppler measurements were noted in patients with vertigo.
    Clinical Rheumatology 02/2009; 28(1):107.
  • Clinical Rheumatology 01/2009;
  • Clinical Rheumatology 10/2008; 27(10):1337-8.
  • [show abstract] [hide abstract]
    ABSTRACT: For over 30 years, investigators have used the simple but non-validated classification criteria suggested by Moll and Wright. Several authors have suggested modifications to these but most remain unvalidated or require human leukocyte antigen analysis. Now, a worldwide initiative has developed new criteria which include both clinical and radiological features. These will require further study before they are fully adopted but their improved performance should result in less variation between study cohorts. The recurring question of disease heterogeneity continues to occupy researchers in this field. Despite recent pleas to abandon the original five sub-groups, a case can be made for retaining at least the two sub-groups of peripheral and axial disease and, possibly, splitting the peripheral disease into oligo- and poly-arthritis.
    Clinical Rheumatology 10/2008; 27(10):1211-6.
  • Clinical Rheumatology 10/2008; 27(10):1339-40.
  • [show abstract] [hide abstract]
    ABSTRACT: Although ibandronate improves suboptimal compliance in patients receiving weekly bisphosphonates, there is a concern about its effect on the reduction of nonvertebral fractures. In the era of evidence-based medicine, randomized clinical trials are considered the highest quality evidence which guide us to the best clinical decision. Nevertheless, if level 1 evidence is not available, as is the case with ibandronate, evidences of lower levels could be used to draw relevant clinical decision. In this article, we discussed data from clinical trials (subgroup analyses of high-risk patients, meta-analysis of clinical trials) which suggested significant effect of ibandronate on the risk reduction of nonvertebral fractures.
    Clinical Rheumatology 10/2008; 27(10):1313-5.

Related Journals